Abstract
Today, the most reliable diagnosis for Alzheimers disease (AD) is the post mortem identification of amyloid plaques, consisting of the Amyloid-β (Aβ) peptide, (and neurofibrillary tangles) in the brain of the patient. Great efforts are being made to identify reliable biomarkers for AD that are suitable for minimal invasive early diagnosis and prognosis of AD. During the past years, body fluids of AD patients were assayed for their content of total or soluble Aβ(1-40) or Aβ(1-42) concentrations using classical (ELISA) or non-classical (with additional signal amplification) read-out. Cerebrospinal fluid (CSF) concentrations of soluble Aβ(1-42) are reduced by 40 to 50 % in AD patients compared to agematched healthy controls as confirmed in more than 30 studies, with both sensitivity and specificity exceeding 80 % in most of the studies. Thus, it was suggested that low levels of CSF Aβ(1-42) might be useful for preclinical diagnosis. Because the current average sensitivity of AD biomarker detection in the CSF is approximately 85 %, these assays do not offer a considerable increase in predictive value over existing algorithms based on neuropsychological and imaging modalities. Regarding the amyloid cascade hypothesis, Aβ oligomers and aggregates are directly involved in the pathogenic process. Therefore, presence of Aβ aggregates seem to be the most direct disease biomarker for AD and increasing effort is being made into the development of methods suitable for the detection of different Aβ aggregates in body fluids like CSF and plasma. We therefore give an overview of the current state of Aβ aggregate specific detection.
Keywords:Alzheimer's disease,early-diagnosis,prognosis,therapy monitoring,Amyloid-β aggregates,protein misfolding diseases,biomarker
Current Alzheimer Research
Title: Detection of Amyloid-β Aggregates in Body Fluids: A Suitable Method for Early Diagnosis of Alzheimers Disease?
Volume: 6Issue: 3
Author(s):S. A. Funke, E. Birkmann and D. Willbold
Affiliation:
Keywords:Alzheimer's disease,early-diagnosis,prognosis,therapy monitoring,Amyloid-β aggregates,protein misfolding diseases,biomarker
Abstract: Today, the most reliable diagnosis for Alzheimers disease (AD) is the post mortem identification of amyloid plaques, consisting of the Amyloid-β (Aβ) peptide, (and neurofibrillary tangles) in the brain of the patient. Great efforts are being made to identify reliable biomarkers for AD that are suitable for minimal invasive early diagnosis and prognosis of AD. During the past years, body fluids of AD patients were assayed for their content of total or soluble Aβ(1-40) or Aβ(1-42) concentrations using classical (ELISA) or non-classical (with additional signal amplification) read-out. Cerebrospinal fluid (CSF) concentrations of soluble Aβ(1-42) are reduced by 40 to 50 % in AD patients compared to agematched healthy controls as confirmed in more than 30 studies, with both sensitivity and specificity exceeding 80 % in most of the studies. Thus, it was suggested that low levels of CSF Aβ(1-42) might be useful for preclinical diagnosis. Because the current average sensitivity of AD biomarker detection in the CSF is approximately 85 %, these assays do not offer a considerable increase in predictive value over existing algorithms based on neuropsychological and imaging modalities. Regarding the amyloid cascade hypothesis, Aβ oligomers and aggregates are directly involved in the pathogenic process. Therefore, presence of Aβ aggregates seem to be the most direct disease biomarker for AD and increasing effort is being made into the development of methods suitable for the detection of different Aβ aggregates in body fluids like CSF and plasma. We therefore give an overview of the current state of Aβ aggregate specific detection.
Export Options
About this article
Cite this article as:
Funke A. S., Birkmann E. and Willbold D., Detection of Amyloid-β Aggregates in Body Fluids: A Suitable Method for Early Diagnosis of Alzheimers Disease?, Current Alzheimer Research 2009; 6 (3) .https://dx.doi.org/10.2174/156720509788486536
| DOI https://dx.doi.org/10.2174/156720509788486536 | Print ISSN 1567-2050 |
| Publisher Name Bentham Science Publisher | Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Blood Tests: Advancements and the Future of Point-of-Care
The recent FDA approval of lecanemab (Leqembi), the first treatment for Alzheimer’s disease targeting early stages and mild cognitive impairment, has brought renewed hope for the therapeutic future of this devastating condition. While the exact causes and mechanisms of Alzheimer’s disease remain obscure, there is an urgent consensus on the ...read more
Atypical Alzheimer’s disease: towards inclusion into disease-modifying clinical trials
Patients with non-amnestic atypical variants of Alzheimer’s disease show considerable heterogeneity in clinical characteristics, including visual, language and behavioral impairments, and often have a young age onset. Current clinical trials for anti-amyloid therapies do not sufficiently account for this heterogeneity, and it is unclear whether current treatments tested in amnestic ...read more
Drug Discovery and Possible Therapeutic Developments in Neurological Disorders Alzheimer’s Disease and Tauopathy
A critical appraisal Alzheimer's disease (AD) is a devastating mental illness in society and the etiology and pathogenesis of AD are still poorly understood. One of the key hallmark pathological proteins of AD is tau, where the pathophysiology and the functional relationships between hyperphosphorylation of tau and synaptic damage in ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neuropharmacology
Current Neurovascular Research
Central Nervous System Agents in Medicinal Chemistry
Current Respiratory Medicine Reviews
Current Pediatric Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Stem Cell Research & Therapy
Related Books
Occupational Therapy Practice in Mental Health: Models, Conditions, Interventions, and Recovery
Research Protocols for Ophthalmic Disease Mechanisms and Therapeutics: Glaucoma - Ocular Hypertension
Current Topics on Renal Dysfunction: From Basics to Clinic
Antibiotics and Reproductive Health
Spinal Surgery Biomechanics: Principles for Residents and Students
Promising Cancer Therapeutic Drug Targets: Recent Advancements
Gut Microbiota and their Impact on Disease Pathways and Interventions
Organ-specific Parasites in Cattle
Infections and Male Infertility: General Pathophysiology, Diagnosis, and Treatment
Advancements in Cancer Research: Exploring Diagnostics and Therapeutic Breakthroughs
29
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
- Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug TargetsAdverse Drug Reactions Related to Drug Administration in Hospitalized Patients
Current Drug SafetyInflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical DesignEtiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current PsychopharmacologyStroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Infective Proteins: The Prion Puzzle
Current Protein & Peptide Science Oxidative Stress in Alzheimer Patients in Different Stages of the Disease
Current Medicinal Chemistry Serotonin Reuptake Inhibitors: The Corner Stone in Treatment of Depression for Half a Century – A Medicinal Chemistry Survey
Current Topics in Medicinal ChemistryCovid-19: An Update on Clinical Features, Diagnosis, and Treatment Strategies
Coronaviruses Autoimmunity in Alzheimers Disease as Evidenced by Plasma Immunoreactivity Against RAGE and Aβ42: Complication of Diabetes
Current Alzheimer ResearchImmune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug TargetsAsymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer’s disease in a Family with Late-onset Dementia
Current Alzheimer ResearchThe Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease
Current Alzheimer Research Ceruloplasmin, the Unique Multi-Copper Oxidase of Vertebrates
Protein & Peptide LettersMemorization Test and Resting State EEG Components in Mild and Subjective Cognitive Impairment
Current Alzheimer ResearchSpecial Invited Article Concussion, Sports and Psychiatry
Adolescent PsychiatryMusic Therapy in the Management of Dementia
Current Psychiatry Research and Reviews Protein Chemistry of Amyloid Fibrils and Chaperones: Implications for Amyloid Formation and Disease
Current Chemical BiologySevere Acute Respiratory Syndrome Coronavirus 2 is Penetrating to Dementia Research
Current Neurovascular Research
[8]ページ先頭